Breast Cancer Liquid Biopsy Market to Reach $336,659 Thousand, Globally, by 2027 at 18.3% CAGR: AMR

News provided by

Nov 10, 2020, 08:10 ET

PORTLAND, Ore., Nov. 10, 2020 /PRNewswire/ -- Allied Market Research published a report, titled, "Breast Cancer Liquid Biopsy Market by Product & Service (Reagent Kits, Instruments, and Services), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, and Circulating Tumor DNA), and Application (Diagnostics, Prognostics, and Risk Assessment): Global Opportunity Analysis and Industry Forecast, 2019–2027."According to the report, the global breast cancer liquid biopsy industry generated $87,641 thousand in 2019, and is expected to garner $ 336,659 thousand by 2027, registering a CAGR of 18.3% from 2019 to 2027.

Download Detailed COVID-19 Impact Sample Report at: https://www.alliedmarketresearch.com/request-for-customization/7983?reqfor=covid

Key determinants in the market-

Rise in demand for safe and non-invasive procedures, increase in prevalence of breast cancer, and benefits offered by breast cancer liquid biopsy tests over traditional tests augment the growth of the global breast cancer liquid biopsy market. Nevertheless, lack of access and awareness in underdeveloped countries impedes the growth to certain extent. Moreover, high growth potential in emerging markets anticipates to usher a plethora of new opportunities in the coming years.

Covid-19 Scenario:

The manufacturing and distribution companies in the breast cancer liquid biopsy industry have been affected due to COVID-19 outbreak.
The lockdowns in various COVID-19 affected countries disrupted the supply chain.

The reagent kit segment to dominate the market by 2027-

Based on product and service, the reagent kit segment garnered the largest market share in 2019, accounting for nearly three-fourths of the global breast cancer liquid biopsy market, and will continue its leadership status throughout the forecast period. In addition to this, the same segment is expected to grow the largest CAGR of 19.4% from 2020 to 2027. This is attributed to the factors such as increase in prevalence of breast cancer, rise in preference for noninvasive procedures, increase in breast cancer liquid biopsy reagents approvals, and increase in funding for liquid biopsy R&D.

The diagnostics segment to lead the trail by 2027-

Based on application, the diagnostics segment accounted for the highest market share in 2019, contributing to more than half of the global breast cancer liquid biopsy market, and is projected to maintain its lead throughout the forecast period. In addition, the segment is also expected to portray the fastest CAGR of 19.5% from 2020 to 2027. Rise in number of patients suffering from breast cancer, technological advancements in liquid biopsy systems, and increase in patient awareness toward safe and non-invasive liquid biopsy testing procedures are the major elements drive the growth of the segment.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/7983

North America to rule the roost throughout the forecast period

Based on region, North America held the largest market share in 2019, with more than two-fifths of the global breast cancer liquid biopsy market, and will maintain its dominance throughout 2027. In addition, this region is estimated to portray the fastest CAGR of 5.6% during the forecast period. This is attributed to the factors such as increase in prevalence of breast cancer, rise in preference of physicians & patients for minimally invasive procedures, availability of advanced healthcare facilities with trained medical professionals, rise in number of R&D activities. Moreover, the market across Asia-Pacific region is expected to grow at the fastest CAGR of 20.0% from 2020 to 2027. Increase in number of breast cancer patients, advantages of breast cancer liquid biopsy tests over traditional tests, and improvement in healthcare facilities in this province augment the growth of the market.

Key players in the market to grab the largest pie-

Biocept, Inc.
F. Hoffmann-La Roche Ltd. (Foundation Medicine, Inc.)
Fluxion Biosciences, Inc.
Menarini Group (Menarini Silicon Biosystems, Inc.)
Myriad Genetics, Inc.
NeoGenomics Laboratories, Inc.
Qiagen N.V.
Sysmex Corporation
Thermo Fisher Scientific Inc.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering impact of Covid-19 over this market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.

Breast Biopsy Market - Global Opportunity Analysis and Industry Forecast, 2019-2027

Liquid Biopsy Market - Global Opportunity Analysis and Industry Forecast, 2019-2027

Prostate Biopsy Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

Lung Biopsy Devices Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

Cancer Biomarkers Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

Biomarkers Market - Global Opportunity Analysis and Industry Forecast, 2019–2027

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research